VENTANA anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody (CE IVD)

Leading the way in HER2 testing

The use of pre-diluted VENTANA anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody¹(VENTANA HER2 (4B5) Antibody), in combination with the fully automated BenchMark IHC/ISH slide staining instrument, standardizes all IHC processes from baking through staining, and reduces the possibility of human error. It also minimizes inherent variability resulting from individual reagent dilution and other processes found in manual and semi-automated IHC methods.

The Roche HER2 (4B5) clone* empowers you to:

Achieve consistently high proficiency assessment scores compared to other clones²
Employ the most widely adopted and reliable HER2-IHC primary antibody²
Demonstrate high concordance with HER2 FISH^3,4

*Refers to the PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody and VENTANA anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody products.

Consistent performance and superior quality

The Roche HER2 (4B5) clone* has shown the most consistent performance and superior quality when compared to other on-market HER2 clones **

* Data refers to PATHWAY and VENTANA products.
**Based on data from a leading external quality assessment scheme. Retrieved from http://www.nordiqc.org/epitope.php

Related links

Breast cancer IHC/ISH portfolio

Roche Diagnostics offers numerous cancer diagnostic assays that enable pathology labs to deliver accurate results with confidence. We provide a robust menu of breast cancer diagnostic tools. Our portfolio of products delivers the high sensitivity and specificity you need from your assays.

BenchMark ULTRA IHC/ISH System

This fully automated instrument offers 30 independent slide drawers and single-piece workflow — supporting the largest menu of 250+ ready-to-use assays.

Digital pathology solution

The combination of innovative hardware, software and image analysis algorithms work in integrated harmony with the full Roche diagnostic portfolio for an end-to-end experience.

References

VENTANA anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody Package Insert.
NordiQC Assessments. http://www.nordiqc.org/epitopes.htm Accessed September 19, 2016.
Mayr D, et al. Comprehensive immunohistochemical analysis of Her-2/neu oncoprotein overexpression in breast cancer: HercepTest™ (Dako) for manual testing and Her-2/neuTest 4B5 (VENTANA) for VENTANA BenchMark automatic staining system with correlation to results of BenchMark automatic staining system with correlation to results of fluorescence in situ hybridization (FISH). Virchows Archiv. 2009; 454(3):241–248.
Brügmann A, Lelkaitis G, Nielsen S, et al. Testing HER2 in breast cancer: a comparative study on BRISH, FISH, and IHC. Appl Immunohistochem Mol Morphol. 2011;19(3):203-211.

Related Topics

Intended use

VENTANA anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody is intended for the semi-quantitative detection of HER2 antigen in sections of formalin-fixed, paraffin-embedded normal and neoplastic breast and gastric tissue on a BenchMark IHC/ISH instrument.

This product is indicated as an aid in the assessment of breast and gastric cancer patients for whom Herceptin^® (trastuzumab) treatment is considered and for breast cancer patients for whom KADCYLA^® (ado-trastuzumab emtansine) or PERJETA^® (pertuzumab) treatments are being considered.

This product should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information, and proper controls.

This antibody is intended for in vitro diagnostic (IVD) use.

Criteria for Intensity and Pattern of Cell Membrane Staining with VENTANA HER2 (4B5) antibody in Breast Carcinoma:

View Full Table

Criteria for Intensity and Pattern of Cell Membrane Staining with VENTANA HER2 (4B5) antibody in Breast Carcinoma:
Staining Pattern	Score (Report to Treating Physician)	HER2 Staining Assessment
No membrane staining is observed	0	Negative
Faint, partial staining of the membrane in any proportion of the cancer cells	1+	Negative
Weak complete staining of the membrane, > 10% of cancer cells	2+	Equivocal*
Intense complete staining of the membrane, > 10% of cancer cells	3+	Positive

* Recommend reflex to ISH

Criteria for Intensity and Pattern of Cell Membrane Staining with VENTANA HER2 (4B5) antibody in Gastric Carcinoma:

View Full Table

Criteria for Intensity and Pattern of Cell Membrane Staining with VENTANA HER2 (4B5) antibody in Gastric Carcinoma:
Staining Pattern - Resection Specimen	Score (Report to requesting physician)	HER2 Staining Assessment
No reactivity or membranous reactivity in < 10% of tumor cells	0	Negative
Faint/barely perceptible membranous reactivity in ≥ 10% of tumor cells; cells are reactive only in part of their membrane	1+	Negative
Weak to moderate complete, basolateral or lateral membranous reactivity in ≥ 10% of tumor cells	2+	Equivocal**
Strong complete, basolateral or lateral membranous reactivity in ≥ 10% of tumor cells	3+	Positive

* ≥ 5 cohesive cells ** Recommend reflex to ISH

View Full Table

Criteria for Intensity and Pattern of Cell Membrane Staining with VENTANA HER2 (4B5) antibody in Gastric Carcinoma:
Staining Pattern -Biopsy Specimen	Score (Report to requesting physician)	HER2 Staining Assessment
No reactivity or membranous reactivity in any tumor cell	0	Negative
Tumor cell cluster* with a faint/barely perceptible membranous reactivity irrespective of percentage of tumor cells stained	1+	Negative
Tumor cell cluster* with a weak to moderate complete, basolateral or lateral membranous reactivity irrespective of percentage of tumor cells stained	2+	Equivocal**
Tumor cell cluster* with a strong complete, basolateral or lateral membranous reactivity irrespective of percentage of tumor cells stained	3+	Positive

* ≥ 5 cohesive cells ** Recommend reflex to ISH

View product details for the VENTANA anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody

Search our product catalogs and documentation library in eLabDoc.

Visit eLabDoc